Propanc

What Propanc does

Propanc Biopharma, Inc. (Nasdaq: PPCB) is a clinical-stage biopharmaceutical company developing a proprietary proenzyme therapy platform for the treatment and prevention of metastatic cancer and other chronic diseases. The company is incorporated in Delaware, headquartered in Melbourne, Australia, and operates with a 1–10 employee base focused on R&D rather than commercial infrastructure; it has been funded to date through equity financings totaling over $30M since inception, including a $4M Nasdaq public offering in August 2025 and an up-to-$100M private placement facility with Hexstone Capital signed in October 2025.

The company's lead asset, PRP, is a world-first fixed-ratio (1:6) combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, administered intravenously. Unlike cytotoxic chemotherapy, PRP is designed to induce cancer cell differentiation — pushing malignant cells back toward a normal phenotype — while targeting cancer stem cells, suppressing epithelial-mesenchymal transition, inhibiting tumor angiogenesis, and modulating the tumor microenvironment, including cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Preclinical pancreatic models have shown greater than 85% tumor growth inhibition, and compassionate-use data from 46 terminal solid-tumor patients (published in Scientific Reports) reported an average 19-month life extension with no severe or serious side effects. The company is also advancing Rec-PRP, a fully synthetic recombinant version intended to enable scalable, refrigerator-stable, animal-free GMP manufacturing. A European CDMO was engaged in May 2026 for end-to-end GMP production, and a service agreement with FyoniBio GmbH (Berlin) was signed in March 2026 to validate a LC-MS/MS pharmacokinetics assay in support of a Phase 1b First-In-Human study planned at the Peter MacCallum Cancer Centre in Melbourne for 30–40 advanced solid-tumor patients. The company is pre-revenue with no product on the market and a 7-year U.S. market exclusivity granted by an FDA Orphan Drug Designation for pancreatic cancer (2017).

Name

Propanc

Legal name

Propanc Biopharma, Inc.

Website

https://propanc.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Propanc Biopharma (Nasdaq: PPCB) is a pre-revenue, clinical-stage biopharmaceutical company developing PRP, a first-in-class fixed-ratio proenzyme (trypsinogen/chymotrypsinogen) therapy that induces differentiation of cancer cells, with a Phase 1b First-In-Human study planned for advanced solid tumors at the Peter MacCallum Cancer Centre.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)

Keywords

• Proenzyme cancer therapy
• Oncology drug development
• Pancreatic cancer treatment
• Biopharmaceutical research
• Solid tumor therapeutics

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue clinical-stage development: Propanc Biopharma is a pre-revenue biopharmaceutical company with no product revenues to date. The condensed consolidated statements of operations for Q3 2025/26 and 9M 2025/26 report zero revenue. All operating expenses are R&D and administration (with large non-cash stock-based compensation components). Future revenue is expected from pharmaceutical sales and/or licensing of PRP and Rec-PRP upon regulatory approval, with a 7-year market exclusivity granted by the FDA Orphan Drug Designation (2017) for pancreatic cancer.
2. Future potential: pharmaceutical sales of PRP / Rec-PRP: Following planned Phase 1b FIH study, Phase 2 proof-of-concept studies in pancreatic and ovarian cancers, and regulatory approval, the company plans to commercialize PRP / Rec-PRP for treatment and prevention of metastatic cancer from solid tumors (initially targeting pancreatic, ovarian, and colorectal cancers), leveraging FDA Orphan Drug exclusivity and 7-year market exclusivity post approval.
3. Digital asset treasury (non-operating): Up to $100M private placement facility from Hexstone Capital is partly intended to support a digital asset acquisition / crypto treasury strategy in addition to funding the R&D pipeline. This represents a non-traditional funding approach for a biotech firm, blending capital markets access with crypto treasury build-out.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Propanc Biopharma is a clinical-stage biopharmaceutical company developing PRP, a proenzyme-based cancer therapy that combines the pancreatic proenzymes trypsinogen and chymotrypsinogen for intravenous administration. The therapy targets advanced solid tumors and cancer stem cells and is being advanced toward clinical development, with an FDA Orphan Drug Designation for pancreatic cancer.

Product overview

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company with a single unified product platform centered on its proenzyme therapy. The core offering is PRP (Proenzyme Therapy), the lead product candidate comprising a synergistic combination of two proenzymes (trypsinogen and chymotrypsinogen) in development for advanced pancreatic cancer and other solid tumors. Building on the same mechanism of action, the company is also developing Rec-PRP, a synthetic recombinant version of PRP intended to enable scalable, GMP-compliant manufacturing for future clinical and commercial supply. Together, PRP and Rec-PRP form the entirety of Propanc's product portfolio, supported by a growing international patent estate and an FDA Orphan Drug Designation for PRP in pancreatic cancer.

Differentiator

Problem solved

Functional benefit

Brands

• PRP: Proprietary proenzyme therapy combining trypsinogen and chymotrypsinogen for cancer treatment
• Rec-PRP

Products and services

• PRP (Proenzyme Therapy) Investigational proenzyme oncology therapy combining trypsinogen and chymotrypsinogen, administered intravenously to treat advanced solid tumors and target cancer stem cells. Intended for oncology hospitals, cancer treatment centers, and specialty oncology providers.
• Rec-PRP (Recombinant Proenzyme Therapy) Synthetic, recombinant proenzyme formulation designed as a next-generation scalable version of PRP for solid tumor treatment, intended to enable consistent, GMP-grade production and broader clinical use.

Quantifiable outcome

• >85% tumor growth inhibition in preclinical pancreatic cancer models
• +5 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered advisory / scientific relationship (honorary guest), core operational partner, flagship research collaboration (17-year relationship) and core clinical trial site.

• Dr. Juan Carlos Izpisúa Belmonte (Altos Labs)advisory / scientific relationship (honorary guest)Strategic or Co-development Partner · 2 June 2026Propanc's CEO attended a keynote address by Dr. Juan Carlos Izpisúa Belmonte (one of the world's foremost scientists in developmental biology and regenerative medicine, affiliated with Altos Labs San Diego Institute of Science) at the University of Granada, with Propanc positioning its research on proenzyme-based cell rejuvenation and EMT reversal as aligned with Altos Labs' research on reversing chronic diseases of aging. Dr. Izpisúa also held a meeting with the Rector of the UGR attended by the Propanc CEO.
• European CDMO (unnamed)core operational partnerStrategic or Co-development Partner · 19 May 2026Engaged a European Contract Development and Manufacturing Organization (CDMO, established 2017) for GMP manufacture of PRP for the Phase 1b FIH study. Provides end-to-end services for preclinical and clinical projects with extensive experience in decoding biologics production (plasmid DNA and recombinant proteins), including cell line generation, banking and characterization, analytical development, process development, and batches production of drug substances and drug products. Operating across two building sites totaling 4,500 sqm (500 sqm development, 1,400 sqm cGMP manufacturing, 400 sqm analytical testing, 400 sqm cGMP warehouse), with multiple ISO certifications (ISO 9001:2015, ISO 13485:2016, ISO 14001:2015) and GMP compliance. Target milestones: pre-production in August 2026, engineering run in October 2026, GMP manufacture commencing December 2026.
• Universities of Jaén (UJA) and Granada (UGR), Spainflagship research collaboration (17-year relationship)Strategic or Co-development Partner · 24 March 2026Multi-year Joint Research Collaboration Agreement — the fifth agreement between Propanc and the universities over a 17-year period, resulting in four patent families filed, five peer-reviewed publications accepted, numerous scientific presentations, and two PhDs and a professorship awarded to research team members. The collaboration involves evaluation of a senescence-modulating (anti-aging) compound to mitigate senescence and to support claims of recently filed fibrosis and cancer-related patent applications. Prof. Macarena Perán Quesada (UJA) oversees management; Prof. Juan Antonio Marchal Corrales (UGR) oversees equipment and experimental designs. Two Postdoctoral Fellows (Dr. Maria Belén Toledo, Dr. Aitor González-Titos) conduct the study.
• FyoniBio GmbH (formerly Glycotope)core operational partnerStrategic or Co-development Partner · 10 March 2026Service agreement with FyoniBio GmbH, a German Contract Development Organization (CDO) based in Berlin (est. 2010), to establish and validate a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify PRP — both proenzymes trypsinogen and chymotrypsinogen, and their activated enzyme forms trypsin and chymotrypsin — from human serum during the Phase 1b FIH study, with sensitivity of at least 0.1 µg/mL. Considered one of three key activities in preparation for the pivotal FIH milestone.
• Peter MacCallum Cancer Centre, Melbourne, Australiacore clinical trial siteImplementation/ SI/ Consulting Partner · 13 January 2026Planned site for the Phase 1b First-In-Human clinical study of PRP in 30-40 advanced cancer patients with solid tumors, expected to be conducted at Peter MacCallum Cancer Centre in Melbourne — described as Australia's largest and most prestigious cancer hospital. Propanc is preparing the clinical trial application for ethics committee submission.

Scale indicators17 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• FibroGen: Established biopharmaceutical company developing therapies for cancer and fibrotic diseases. Comparable in its pursuit of oncology and fibrosis indications, though FibroGen is larger, more diversified, and at a later commercialization stage.
• RedHill Biopharma: Specialty biopharmaceutical company with a portfolio of commercial and late-stage clinical assets, including oncology programs targeting solid tumors. Comparable as a small/mid-cap public biotech with a similarly small headcount and multiple specialty therapeutic programs.

Emerging players

• Galectin Therapeutics: Clinical-stage biotech developing galectin-3 inhibitors for cancer and fibrosis (including NASH-related cirrhosis). Comparable overlap with Propanc in exploring the same EMT/fibrosis biology for both oncology and age-related chronic disease indications.

Direct peers

• BioLineRx: Clinical-stage biopharmaceutical company developing oncology therapies with a focus on pancreatic cancer (motixafortide). Comparable in scale, stage, and indication focus to Propanc, with a single lead oncology asset in advanced clinical development.
• Moleculin Biotech: Pre-revenue, clinical-stage oncology biotech developing small-molecule therapies for hard-to-treat cancers. Comparable as a small-cap, single-platform oncology company advancing lead assets through early-phase clinical trials.
• Aprea Therapeutics: Clinical-stage oncology biotech developing small molecules that reactivate tumor suppressor pathways in solid tumors. Comparable as a small, pre-commercial public biotech pursuing a single differentiated mechanism in difficult-to-treat cancers.
• Rafael Pharmaceuticals: Oncology company developing devimistat (CPI-613) for pancreatic cancer and other solid tumors. Comparable as a late-stage pre-commercial biotech targeting the pancreatic cancer orphan population with a single novel mechanism asset.
• Oncolytics Biotech: Clinical-stage immuno-oncology biotech developing pelareorep across multiple solid tumor indications, including pancreatic cancer. Directly comparable as a small-cap, pre-revenue oncology platform with a single lead asset advancing through early-phase trials.
• Targovax: Clinical-stage immuno-oncology company developing oncolytic virus and RAS-peptide vaccine therapies for pancreatic and other solid tumors. Comparable in being a small-cap, pre-commercial biotech with a primary focus on difficult-to-treat solid tumors and orphan-indication strategy.

Others

• Lumos Pharma: Clinical-stage rare-disease biotech (inheriting the NewLink Genetics oncology vaccine platform). Tangentially comparable as a small public biotech developing therapeutics for indications with high unmet need and orphan-drug eligibility, though focused on endocrine/metabolic diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/propanc-health-group-corp

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Propanc